trial · primary record
KL003 Cell Injection Drug Product
Transfusion-dependent Beta-Thalassemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 41 |
| Primary completion | 2028-12-20 |
| Primary endpoint | KL003 engraftment |
| Registry ID | NCT06280378 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:29.247Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06280378
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.